INTRODUCTION: Some studies have found that antidepressants increase serum brain-derived neurotrophic factor (BDNF) levels in patients with major depression and the expression of BDNF mRNA in limbic structures of rats. OBJECTIVES: This study addressed whether the SSRI escitalopram increases serum BDNF levels in subjects with PTSD and whether BDNF levels are associated with treatment response. METHODS: Medically healthy male subjects (N=16) with chronic PTSD completed a 12 week open-label trial of flexible dose (5-20 mg/day) escitalopram monotherapy. BDNF levels were obtained at baseline, and at weeks 4, 8 and 12. RESULTS: PTSD symptoms significantly declined over the course of the 12 week escitalopram treatment. Despite a substantial improvement in PTSD symptoms, there was virtually no change in BDNF levels over time. Nevertheless, mean BDNF levels across the trial were strongly correlated with the slope of PTSD symptoms over the 12 weeks (r=0.58, p=0.018). Lower mean BDNF was associated with a greater decrease in PTSD symptoms over the course of the trial. CONCLUSIONS: PTSD subjects with low BDNF levels demonstrated the largest treatment response from an agent with putative neurotrophic effects.
INTRODUCTION: Some studies have found that antidepressants increase serum brain-derived neurotrophic factor (BDNF) levels in patients with major depression and the expression of BDNF mRNA in limbic structures of rats. OBJECTIVES: This study addressed whether the SSRI escitalopram increases serum BDNF levels in subjects with PTSD and whether BDNF levels are associated with treatment response. METHODS: Medically healthy male subjects (N=16) with chronic PTSD completed a 12 week open-label trial of flexible dose (5-20 mg/day) escitalopram monotherapy. BDNF levels were obtained at baseline, and at weeks 4, 8 and 12. RESULTS:PTSD symptoms significantly declined over the course of the 12 week escitalopram treatment. Despite a substantial improvement in PTSD symptoms, there was virtually no change in BDNF levels over time. Nevertheless, mean BDNF levels across the trial were strongly correlated with the slope of PTSD symptoms over the 12 weeks (r=0.58, p=0.018). Lower mean BDNF was associated with a greater decrease in PTSD symptoms over the course of the trial. CONCLUSIONS:PTSD subjects with low BDNF levels demonstrated the largest treatment response from an agent with putative neurotrophic effects.
Authors: Anke Karl; Michael Schaefer; Loretta S Malta; Denise Dörfel; Nicolas Rohleder; Annett Werner Journal: Neurosci Biobehav Rev Date: 2006-05-26 Impact factor: 8.989
Authors: Marek Lommatzsch; Doerte Zingler; Katharina Schuhbaeck; Katharina Schloetcke; Christiana Zingler; Peter Schuff-Werner; Johann Christian Virchow Journal: Neurobiol Aging Date: 2005-01 Impact factor: 4.673
Authors: Sophie Robert; Mark B Hamner; Helen G Ulmer; Jeffrey P Lorberbaum; Valerie L Durkalski Journal: J Clin Psychiatry Date: 2006-10 Impact factor: 4.384
Authors: Magdalena N Jayatissa; Christina Bisgaard; Anders Tingström; Mariusz Papp; Ove Wiborg Journal: Neuropsychopharmacology Date: 2006-02-08 Impact factor: 7.853
Authors: Olivier Berton; Colleen A McClung; Ralph J Dileone; Vaishnav Krishnan; William Renthal; Scott J Russo; Danielle Graham; Nadia M Tsankova; Carlos A Bolanos; Maribel Rios; Lisa M Monteggia; David W Self; Eric J Nestler Journal: Science Date: 2006-02-10 Impact factor: 47.728
Authors: Y Matsuoka; D Nishi; Y Tanima; M Itakura; M Kojima; K Hamazaki; H Noguchi; T Hamazaki Journal: Transl Psychiatry Date: 2015-07-07 Impact factor: 6.222